[{"id":"57397363-0511-4a2f-8250-e63a2ec68211","acronym":"","url":"https://clinicaltrials.gov/study/NCT05018273","created_at":"2021-08-24T11:52:53.229Z","updated_at":"2024-07-02T16:35:07.237Z","phase":"Phase 1","brief_title":"Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors","source_id_and_acronym":"NCT05018273","lead_sponsor":"Nykode Therapeutics ASA","biomarkers":" CRP","pipe":" | ","alterations":" MSI-H/dMMR","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • VB10.NEO"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-29"}]